- Understanding the prevalence, timing and consequences of cardiovascular and renal disease in T2D patients
- Moving beyond glycaemic control to protect kidney function and reduce the risk of cardiovascular disease
- Initiating guideline-directed treatments at an early stage to reduce the risk of cardiorenal complications
- Recognise the importance of cardiorenal complications in T2D
- Learn how to reduce the risk of renal and cardiovascular disease while lowering blood sugar
- Understand new guideline-directed treatments and management tools currently available for practitioners
Prof Josep M. Vilaseca
Prof. Chantal Mathieu
Professor of Medicine at the Katholieke Universiteit and Chair of Endocrinology at the University Hospital Gasthuisberg Leuven, Belgium
Chantal Mathieu is a physician-scientist who has contributed to the field of diabetes and endocrinology through basic and clinical research. Her work in animal models of type 1 diabetes established 1,25-dihydroxyvitamin D3 as an immune modulator and demonstrated the potential of Lactococcus Lactis as a carrier tool for peptides and proteins, which became the basis for a worldwide clinical trial in people with newly diagnosed type 1 diabetes. Her research group was amongst the first to demonstrate the relevance of post-translational modifications of beta-cell peptides and proteins in autoantigen generation in murine and human type 1 diabetes. Prof. Mathieu’s clinical work involving new products and treatment paradigms in diabetes, such as new insulins, adjunct therapies and diagnosis of gestational diabetes as well as her educational skills have made her a prominent speaker in international fora. She has promoted shared-care, positioning of diabetes education and reimbursement of novel technologies. Prof. Mathieu is co-author of several consensus papers, including the 2018-19 ADA/EASD Consensus on glucose lowering therapies in type 2 diabetes. Prof. Mathieu leads the INNODIA project and established its Patient Advisory Committee. Prof. Mathieu is also (senior) vice-president of EASD, Chair of postgraduate education and Chair of the European Diabetes Forum.
Dr. Baruch Itzhak
Specialist in Family Medicine and Diabetologist at Clalit Health Services; Haifa district; Israel.
He graduated with a degree in medicine at Tel-Aviv university in 1986. He received his medical degree of Family Medicine at the Technion faculty of medicine, Haifa in 1994. Dr. Itzhak is working as a clinician and diabetologist in primary care settings of Clalit Health Services in Israel. He is recognized as a teacher for medical students and residents in Family Medicine and Diabetes, and the project coordinator for ' Diabetes Education and Quality Assurance in the Community'. He is a member of the Israel Association of Family Physicians, Israel National Diabetes council and the Israel Diabetes Association , and is involved in national projects for Diabetes and its Prevention. Dr. Itzhak is a clinical investigator in Diabetes, Lipids and Hypertension Research Unit, Lin Medical Center, where he is involved in multiple clinical studies. His special interest is in prevention of Diabetes and complications, early initiation and intensification of Insulin therapy among primary care providers. He has published many articles related to Diabetes in primary care. He is an active speaker in national and international conferences, and has participated in many advisory panels. He is the current secretary of the D & CVD Study Group of the EASD and a council member of EPCCS. He is an active member of WONCA Europe.
This webinar is supported by an unrestricted educational grant from AstraZeneca.